How Much Weight Do People Typically Lose on Wegovy in the First Month?

Why the first month's numbers look smaller than the headlines

The STEP 1 trial, which randomised 1,961 adults with obesity across 68 weeks, is the most cited evidence for Wegovy's effectiveness. At 2.4 mg weekly, participants lost an average of around 15% of their body weight. That is the full-course figure. Breaking it down by phase, earlier trial reporting and clinical observation consistently show that weight loss in the first four weeks is modest, typically in the 1–3 kg range for many participants, because the dose during that window is 0.25 mg — a level set specifically to reduce the chance of nausea and other gastrointestinal side effects rather than to suppress appetite substantially.

Think of it less as the medicine failing and more as the medicine settling in. The 0.25 mg pen goes in once a week, and for many people it sits in the fridge door next to everything else, almost unremarkable. That ordinariness is intentional: Novo Nordisk designed the titration schedule so the body adjusts gradually before higher doses arrive. Prescribers increase the dose roughly every four weeks, meaning most patients reach the therapeutic 1.0 mg mark only around week nine. Expecting dramatic results before that point sets an unfair benchmark. Our overview of how long Wegovy takes to work covers this timeline in more detail.

One more factor: water weight and appetite-driven calorie reduction both contribute to early numbers, which can flatter the first fortnight and then level off. Neither effect is a sign something has gone wrong.

What a realistic first-month figure looks like, and when the pace picks up

Clinical data and post-marketing reports suggest a typical first-month loss of roughly 2–5% of starting body weight for people who follow the prescribed titration. For someone starting at 100 kg, that is approximately 2–5 kg. Some people see less, particularly if gastrointestinal side effects have made eating uncomfortable rather than producing deliberate calorie reduction. Others see more, especially if dietary changes have been significant from day one.

The pace reliably increases from month three onward, as the dose climbs. The three-month picture is markedly different from month one, and results continue building from there. By six months, with many patients at or near the 2.4 mg maintenance dose, the cumulative average in trial populations was considerably higher. If you want to see how those numbers compare across the full treatment arc, the six-month data gives the fuller story.

It is also worth reading the STEP 1 figure carefully: 15% average over 68 weeks means some participants lost more and some less. Trial populations include everyone who was randomised, including those who stopped early. Real-world results can differ from controlled trial conditions. The NHS medicines page for semaglutide offers a straightforward summary of what is known about how the medicine works and what to expect.

What can affect your personal result in month one

Several things shape how the first month goes, none of them are willpower. Starting weight matters: a higher baseline body weight often produces a larger absolute number even at a low percentage. Diet changes made alongside treatment amplify early results, because the medicine gradually reduces appetite but does not override food choices entirely. Physical activity similarly accelerates the calorie deficit.

Side effects can complicate the picture in month one. Nausea, the most commonly reported symptom at initiation, sometimes leads people to eat less than planned or to choose different foods, which can push the scale down quickly but inconsistently. Our page on nausea onset with Wegovy covers what to expect and when it typically settles.

Dose tolerance also varies. Some people titrate on schedule with no interruption; others stay at a lower dose for an extra four weeks on their prescriber's advice, which delays but does not prevent therapeutic-level results. There is no value in rushing the schedule. A prescriber's ongoing involvement is not just a regulatory box to tick — it is the thing that catches those situations early and adjusts the plan accordingly. If you are thinking about what this could mean for your own situation, our overview of Wegovy weight loss across the full treatment period puts the month-one phase into the broader context. And for anyone comparing treatments before they have started, the Wegovy treatment guide covers eligibility, licensing and how a private prescription works.

These are prescription-only medicines, and suitability is assessed individually. If you would like to explore whether Wegovy could be right for you, check your eligibility with our clinical team, a GPhC-registered prescriber reviews every consultation the same day.